Cydan spins out rare endocrine company Tiburio with $31M, Ipsen compounds

Tiburio Therapeutics Inc. (Cambridge, Mass.) launched Jan. 3 with a $31 million series A round and two clinical compounds licensed from Ipsen Group (Euronext:IPN; Pink:IPSEY) that it plans to develop for rare neuroendocrine tumors and rare endocrine diseases.

Tiburio spun out of Cydan Development Inc. (Cambridge, Mass.), which creates companies to de-risk and develop assets sourced from academia, not-for-profits and industry...